EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieÄquivalenzstudieOpen Access

Biodegradable or durable polymer drug-eluting stents in patients with coronary artery disease: ten-year outcomes of the randomised NEXT Trial

Masahiro Natsuaki, Hirotoshi Watanabe, Takeshi Morimoto, Ken Kozuma, Kazushige Kadota, Toshiya Muramatsu, Yoshihisa Nakagawa, Takashi Akasaka, Keiichi Igarashi Hanaoka, Kengo Tanabe, Yoshihiro Morino, Tetsuya Ishikawa und 11 weitere

EuroIntervention · 2023-08 · 19 (5) · e402-e413

DOI: 10.4244/eij-d-23-00076 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift EuroIntervention, 2023-08. Verfasst von Masahiro Natsuaki und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Medicine, Saga University, Saga, Japan. Hauptthemen laut MEDLINE: Coronary Artery Disease, Drug-Eluting Stents, Myocardial Infarction, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: There are no randomised trials reporting clinical outcomes of biodegradable polymer biolimus-eluting stents (BP-BES) and durable polymer everolimus-eluting stents (DP-EES) at 10 years. AIMS: We aimed to compare the 10-year clinical outcomes between BP-BES and DP-EES. METHODS: The randomised NOBORI Biolimus-Eluting Versus XIENCE/PROMUS Everolimus-eluting Stent Trial (NEXT) was originally designed to evaluate the non-inferiority of BP-BES relative to DP-EES with the primary efficacy endpoint of target lesion revascularisation (TLR) at 1 year and the primary safety endpoint of death or myocardial infarction (MI) at 3 years. In this extended follow-up study, clinical outcomes were compared from 1 year after stent implantation up to 10 years between patients with BP-BES and DP-EES. RESULTS: From May to October 2011, NEXT enrolled a total of 3,241 patients from 98 centres in Japan. The current study population consisted of 2,417 patients (1,204 patients with BP-BES and 1,213 with DP-EES) from 66 centres that agreed to participate in the extended study. Complete 10-year follow-up was achieved in 87.5% of patients. The cumulative 10-year incidence of death or MI was 34.0% in the BP-BES group and 33.1% in the DP-EES group (hazard ratio [HR] 1.04, 95% confidence interval [CI]: 0.90-1.20; p=0.58). TLR occurred in 15.9% of patients in the BP-BES group and in 14.1% of the DP-EES group (HR 1.12, 95% CI: 0.90-1.40; p=0.32). In a landmark analysis at 1 year, the cumulative incidences of death or MI and TLR were not significantly different between the 2 groups. CONCLUSIONS: The safety and efficacy outcomes for BP-BES were not significantly different from those for DP-EES at 1 year and up to 10 years after stent implantation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Coronary Artery DiseaseDrug-Eluting StentsMyocardial InfarctionPercutaneous Coronary InterventionHumansAbsorbable ImplantsEverolimusFollow-Up StudiesPolymersSirolimusTreatment OutcomeAlkanesulfonic Acids

Substanzen

EverolimusPolymersSirolimusBESAlkanesulfonic Acids

Autor:innen und Institutionen

  • Department of Cardiovascular Medicine, Saga University, Saga, Japan.
  • Division of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan.
  • Department of Clinical Epidemiology, Hyogo College of Medicine, Nishinomiya, Japan.
  • Department of Cardiology, Teikyo University Hospital, Tokyo, Japan.
  • Department of Cardiovascular Medicine, Kurashiki Central Hospital, Kurashiki, Japan.
  • Division of Cardiology, Tokyo Kamata Hospital, Tokyo, Japan.

Zitieren

APA

Natsuaki, M., Watanabe, H., Morimoto, T., Kozuma, K., Kadota, K., Muramatsu, T., Nakagawa, Y., Akasaka, T., Hanaoka, K. I., Tanabe, K., Morino, Y., Ishikawa, T., Katoh, H., Nishikawa, H., Tamura, T., Ono, K., Yamamoto, K., Ishihara, T., Abe, M., …, & Kimura, T. (2023). Biodegradable or durable polymer drug-eluting stents in patients with coronary artery disease: ten-year outcomes of the randomised NEXT Trial. EuroIntervention, 19(5), e402-e413. https://doi.org/10.4244/eij-d-23-00076

Vancouver

Natsuaki M, Watanabe H, Morimoto T, Kozuma K, Kadota K, Muramatsu T, et al. Biodegradable or durable polymer drug-eluting stents in patients with coronary artery disease: ten-year outcomes of the randomised NEXT Trial. EuroIntervention. 2023;19(5):e402-e413. doi:10.4244/eij-d-23-00076

BibTeX
@article{Natsuaki2023,
  author = {Natsuaki, Masahiro and Watanabe, Hirotoshi and Morimoto, Takeshi and Kozuma, Ken and Kadota, Kazushige and Muramatsu, Toshiya and Nakagawa, Yoshihisa and Akasaka, Takashi and Hanaoka, Keiichi Igarashi and Tanabe, Kengo and Morino, Yoshihiro and Ishikawa, Tetsuya and Katoh, Harumi and Nishikawa, Hideo and Tamura, Toshihiro and Ono, Koh and Yamamoto, Ko and Ishihara, Takayuki and Abe, Mitsuru and Taniguchi, Ryoji and Ikari, Yuji and Okada, Kozo and Kimura, Takeshi},
  title = {Biodegradable or durable polymer drug-eluting stents in patients with coronary artery disease: ten-year outcomes of the randomised NEXT Trial},
  journal = {EuroIntervention},
  year = {2023},
  volume = {19},
  number = {5},
  pages = {e402--e413},
  doi = {10.4244/eij-d-23-00076}
}
Kostenlos starten →